THE MEDICAL MANAGEMENT OF STROKE

The management of stroke, so long a ‘Cinderella’ condition, is changing rapidly as new developments appear for acute treatment, rehabilitation and secondary prevention. Most patients with acute stroke now need rapid assessment at hospital following the onset of symptoms. Those needing admission should be managed on an acute stroke unit for stabilisation, CT scanning and other investigation, and diagnosis, and then referred, as appropriate, to a specialist stroke rehabilitation unit. Aspirin is now the recognised treatment for acute ischaemic stroke (once primary Intracerebral haemorrhage has been excluded), and can be continued for secondary prevention. Attention should be paid to risk factors to prevent recurrence, especially treatment of hypertension, atrial fibrillation, and severe ipsilateral carotid stenosis. Patients with mild cerebrovascular disease should be managed in a specialist stroke/TIA clinic. Stroke is no longer an untreatable or unpreventable condition, and It is vital that hospitals design appropriate systems to manage patients in an interdisciplinary environment.

[1]  W. Dick,et al.  Stroke--a medical emergency. , 1999, Journal of accident & emergency medicine.

[2]  J. Grotta Lubeluzole treatment of acute ischemic stroke. The US and Canadian Lubeluzole Ischemic Stroke Study Group. , 1997, Stroke.

[3]  Zheng-Ming Chen,et al.  CAST: randomised placebo-controlled trial of early aspirin use in 20 000 patients with acute ischaemic stroke , 1997, The Lancet.

[4]  C. Forbes,et al.  EUROPEAN STROKE PREVENTION STUDY 2: DIPYRIDAMOLE AND ACETYLSALICYLIC ACID IN THE SECONDARY PREVENTION OF STROKE , 1997, International journal of clinical practice.

[5]  Peter Sandercock,et al.  The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19 435 patients with acute ischaemic stroke , 1997, The Lancet.

[6]  P. Bell,et al.  Carotid and Vertebral Artery Transluminal Angioplasty Study , 1997, The Lancet.

[7]  Langhorne,et al.  Collaborative systematic review of the randomised trials of organised inpatient (stroke unit) care after stroke , 1997, BMJ.

[8]  A. Dávalos,et al.  Progression of ischaemic stroke and excitotoxic aminoacids , 1997, The Lancet.

[9]  H. Diener,et al.  Termination of Acute Stroke Studies Involving Selfotel Treatment , 1997, The Lancet.

[10]  P. Bath Streptokinase increased mortality in acute ischemic stroke , 1997, Evidence Based Medicine.

[11]  W. Marshall,et al.  Changes in Serum Lipid Measurements following Acute Ischaemic Stroke , 1997 .

[12]  David Schultz,et al.  A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) , 1996, The Lancet.

[13]  P. Hamet,et al.  Shanghai trial of nifedipine in the elderly , 1996 .

[14]  I. Aboderin,et al.  Stroke management in Europe , 1996 .

[15]  G. Hankey,et al.  Streptokinase for acute ischemic stroke with relationship to time of administration: Australian Streptokinase (ASK) Trial Study Group. , 1996, JAMA.

[16]  W. J. Hamilton,et al.  Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial , 1996, The Lancet.

[17]  J. Slattery,et al.  Blood pressure and risk of stroke in patients with cerebrovascular disease , 1996, BMJ.

[18]  M. Hommel,et al.  Thrombolytic therapy with streptokinase in acute ischemic stroke. , 1996, The New England journal of medicine.

[19]  W Ceusters,et al.  Endarterectomy for moderate symptomatic carotid stenosis: interim results from the MRC European Carotid Surgery Trial , 1996, The Lancet.

[20]  C. Anderson,et al.  BLOOD PRESSURE LOWERING IN PATIENTS WITH CEREBROVASCULAR DISEASE: RESULTS OF THE PROGRESS (PERINDOPRIL PROTECTION AGAINST RECURRENT STROKE STUDY) PILOT PHASE , 1996, Clinical and experimental pharmacology & physiology.

[21]  P. Hamet,et al.  Shanghai trial of nifedipine in the elderly (STONE). , 1996, Journal of hypertension.

[22]  P. Bath,et al.  Do Acute Stroke Units Improve Care , 1996 .

[23]  P. Bath,et al.  The King's College Hospital Acute Stroke Unit , 1996, Journal of the Royal College of Physicians of London.

[24]  D. Kromhout Cholesterol, diastolic blood pressure, and stroke: 13 000 strokes in 450 000 people in 45 prospective cohorts , 1995, The Lancet.

[25]  A. Ahuja,et al.  Low-molecular-weight heparin for the treatment of acute ischemic stroke , 1995 .

[26]  S. Ebrahim,et al.  Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men , 1995, The Lancet.

[27]  A. Davies,et al.  Endarterectomy for asymptomatic carotid artery stenosis , 1995, BMJ.

[28]  M. Kaste,et al.  Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS) , 1995, JAMA.

[29]  P. Bath Treating acute ischaemic stroke , 1995, BMJ.

[30]  C. Furberg,et al.  Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II) , 1995, The American journal of cardiology.

[31]  J. Grotta Why do all drugs work in animals but none in stroke patients? 2 Neuroprotective therapy , 1995, Journal of internal medicine.

[32]  B. Olofsson,et al.  Atenolol in Secondary Prevention after Stroke , 1995 .

[33]  J. Wardlaw Is routine computed tomography in strokes unnecessary? , 1994, BMJ.

[34]  Scandinavian Simvastatin Survival Study Group Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) , 1994, The Lancet.

[35]  Walker,et al.  Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients , 1994 .

[36]  M. Alberts Tissue plasminogen activator in acute stroke. , 1993, AJNR. American journal of neuroradiology.

[37]  A. Morris,et al.  The experiences of an acute stroke unit--implications for multicentre acute stroke trials. , 1993, Journal of neurology, neurosurgery, and psychiatry.

[38]  I. Perry,et al.  Salt intake and stroke: a possible direct effect. , 1992, Journal of human hypertension.

[39]  M. Laakso,et al.  The European Stroke Prevention Study , 1991, Neurology.

[40]  C. Warlow,et al.  MRC European Carotid Surgery Trial: interim results for symptomatic patients with severe (70-99%) or with mild (0-29%) carotid stenosis , 1991, The Lancet.

[41]  R. Collins,et al.  Blood pressure, stroke, and coronary heart disease Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context , 1990, The Lancet.

[42]  V. Hachinski,et al.  THE CANADIAN AMERICAN TICLOPIDINE STUDY (CATS) IN THROMBOEMBOLIC STROKE , 1989, The Lancet.

[43]  Final report on the aspirin component of the ongoing Physicians' Health Study. , 1989, The New England journal of medicine.

[44]  V. Rich Personal communication , 1989, Nature.

[45]  R. Doll,et al.  Randomised trial of prophylactic daily aspirin in British male doctors , 1988, British medical journal.